Cargando…

Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine

BACKGROUND: Longitudinal neuroimaging studies of major depressive disorder (MDD) have most commonly assessed the effects of antidepressants from the serotonin reuptake inhibitor class and usually reporting a single measure. Multimodal neuroimaging assessments were acquired from MDD patients during a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Cynthia HY, Costafreda, Sergi G, Sankar, Anjali, Adams, Tracey M, Rasenick, Mark M, Liu, Peng, Donati, Robert, Maglanoc, Luigi A, Horton, Paul, Marangell, Lauren B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417267/
https://www.ncbi.nlm.nih.gov/pubmed/25880400
http://dx.doi.org/10.1186/s12888-015-0457-2
_version_ 1782369344363167744
author Fu, Cynthia HY
Costafreda, Sergi G
Sankar, Anjali
Adams, Tracey M
Rasenick, Mark M
Liu, Peng
Donati, Robert
Maglanoc, Luigi A
Horton, Paul
Marangell, Lauren B
author_facet Fu, Cynthia HY
Costafreda, Sergi G
Sankar, Anjali
Adams, Tracey M
Rasenick, Mark M
Liu, Peng
Donati, Robert
Maglanoc, Luigi A
Horton, Paul
Marangell, Lauren B
author_sort Fu, Cynthia HY
collection PubMed
description BACKGROUND: Longitudinal neuroimaging studies of major depressive disorder (MDD) have most commonly assessed the effects of antidepressants from the serotonin reuptake inhibitor class and usually reporting a single measure. Multimodal neuroimaging assessments were acquired from MDD patients during an acute depressive episode with serial measures during a 12-week treatment with the serotonin-norepinephrine reuptake inhibitor (SNRI) duloxetine. METHODS: Participants were medication-free MDD patients (n = 32; mean age 40.2 years) in an acute depressive episode and healthy controls matched for age, gender, and IQ (n = 25; mean age 38.8 years). MDD patients received treatment with duloxetine 60 mg daily for 12 weeks with an optional dose increase to 120 mg daily after 8 weeks. All participants had serial imaging at weeks 0, 1, 8, and 12 on a 3 Tesla magnetic resonance imaging (MRI) scanner. Neuroimaging tasks included emotional facial processing, negative attentional bias (emotional Stroop), resting state functional MRI and structural MRI. RESULTS: A significant group by time interaction was identified in the anterior default mode network in which MDD patients showed increased connectivity with treatment, while there were no significant changes in healthy participants. In the emotional Stroop task, increased posterior cingulate activation in MDD patients normalized following treatment. No significant group by time effects were observed for happy or sad facial processing, including in amygdala responsiveness, or in regional cerebral volumes. Reduced baseline resting state connectivity within the orbitofrontal component of the default mode network was predictive of clinical response. An early increase in hippocampal volume was predictive of clinical response. CONCLUSIONS: Baseline resting state functional connectivity was predictive of subsequent clinical response. Complementary effects of treatment were observed from the functional neuroimaging correlates of affective facial expressions, negative attentional bias, and resting state. No significant effects were observed in affective facial processing, while the interaction effect in negative attentional bias and individual group effects in resting state connectivity could be related to the SNRI class of antidepressant medication. The specificity of the observed effects to SNRI pharmacological treatments requires further investigation. TRIAL REGISTRATION: Registered at clinicaltrials.gov (NCT01051466). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12888-015-0457-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4417267
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44172672015-05-03 Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine Fu, Cynthia HY Costafreda, Sergi G Sankar, Anjali Adams, Tracey M Rasenick, Mark M Liu, Peng Donati, Robert Maglanoc, Luigi A Horton, Paul Marangell, Lauren B BMC Psychiatry Research Article BACKGROUND: Longitudinal neuroimaging studies of major depressive disorder (MDD) have most commonly assessed the effects of antidepressants from the serotonin reuptake inhibitor class and usually reporting a single measure. Multimodal neuroimaging assessments were acquired from MDD patients during an acute depressive episode with serial measures during a 12-week treatment with the serotonin-norepinephrine reuptake inhibitor (SNRI) duloxetine. METHODS: Participants were medication-free MDD patients (n = 32; mean age 40.2 years) in an acute depressive episode and healthy controls matched for age, gender, and IQ (n = 25; mean age 38.8 years). MDD patients received treatment with duloxetine 60 mg daily for 12 weeks with an optional dose increase to 120 mg daily after 8 weeks. All participants had serial imaging at weeks 0, 1, 8, and 12 on a 3 Tesla magnetic resonance imaging (MRI) scanner. Neuroimaging tasks included emotional facial processing, negative attentional bias (emotional Stroop), resting state functional MRI and structural MRI. RESULTS: A significant group by time interaction was identified in the anterior default mode network in which MDD patients showed increased connectivity with treatment, while there were no significant changes in healthy participants. In the emotional Stroop task, increased posterior cingulate activation in MDD patients normalized following treatment. No significant group by time effects were observed for happy or sad facial processing, including in amygdala responsiveness, or in regional cerebral volumes. Reduced baseline resting state connectivity within the orbitofrontal component of the default mode network was predictive of clinical response. An early increase in hippocampal volume was predictive of clinical response. CONCLUSIONS: Baseline resting state functional connectivity was predictive of subsequent clinical response. Complementary effects of treatment were observed from the functional neuroimaging correlates of affective facial expressions, negative attentional bias, and resting state. No significant effects were observed in affective facial processing, while the interaction effect in negative attentional bias and individual group effects in resting state connectivity could be related to the SNRI class of antidepressant medication. The specificity of the observed effects to SNRI pharmacological treatments requires further investigation. TRIAL REGISTRATION: Registered at clinicaltrials.gov (NCT01051466). ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12888-015-0457-2) contains supplementary material, which is available to authorized users. BioMed Central 2015-04-14 /pmc/articles/PMC4417267/ /pubmed/25880400 http://dx.doi.org/10.1186/s12888-015-0457-2 Text en © Fu et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Fu, Cynthia HY
Costafreda, Sergi G
Sankar, Anjali
Adams, Tracey M
Rasenick, Mark M
Liu, Peng
Donati, Robert
Maglanoc, Luigi A
Horton, Paul
Marangell, Lauren B
Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine
title Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine
title_full Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine
title_fullStr Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine
title_full_unstemmed Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine
title_short Multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine
title_sort multimodal functional and structural neuroimaging investigation of major depressive disorder following treatment with duloxetine
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417267/
https://www.ncbi.nlm.nih.gov/pubmed/25880400
http://dx.doi.org/10.1186/s12888-015-0457-2
work_keys_str_mv AT fucynthiahy multimodalfunctionalandstructuralneuroimaginginvestigationofmajordepressivedisorderfollowingtreatmentwithduloxetine
AT costafredasergig multimodalfunctionalandstructuralneuroimaginginvestigationofmajordepressivedisorderfollowingtreatmentwithduloxetine
AT sankaranjali multimodalfunctionalandstructuralneuroimaginginvestigationofmajordepressivedisorderfollowingtreatmentwithduloxetine
AT adamstraceym multimodalfunctionalandstructuralneuroimaginginvestigationofmajordepressivedisorderfollowingtreatmentwithduloxetine
AT rasenickmarkm multimodalfunctionalandstructuralneuroimaginginvestigationofmajordepressivedisorderfollowingtreatmentwithduloxetine
AT liupeng multimodalfunctionalandstructuralneuroimaginginvestigationofmajordepressivedisorderfollowingtreatmentwithduloxetine
AT donatirobert multimodalfunctionalandstructuralneuroimaginginvestigationofmajordepressivedisorderfollowingtreatmentwithduloxetine
AT maglanocluigia multimodalfunctionalandstructuralneuroimaginginvestigationofmajordepressivedisorderfollowingtreatmentwithduloxetine
AT hortonpaul multimodalfunctionalandstructuralneuroimaginginvestigationofmajordepressivedisorderfollowingtreatmentwithduloxetine
AT marangelllaurenb multimodalfunctionalandstructuralneuroimaginginvestigationofmajordepressivedisorderfollowingtreatmentwithduloxetine